Oncopeptides Rescinds Pepaxto Voluntary Withdrawal, Which Could Set Up Battle With US FDA

 
• By Derrick Gingery
  
U-turn sign
An Oncopeptides executive said more information on the decision to rescind the withdrawal is expected in the coming months. • Source: Alamy
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D